epiplakin 1 Activators
Forskolin, by increasing intracellular cAMP levels, can activate PKA, which is known to phosphorylate various proteins, potentially influencing epiplakin 1's interaction with intermediate filaments. Phorbol 12-myristate 13-acetate (PMA) is another activator of PKC, which could lead to a change in the phosphorylation state of proteins associated with the cytoskeleton, thereby potentially enhancing epiplakin 1's functional engagement with keratin filaments. Similarly, EGF, through the activation of the MAPK/ERK pathway, may modify the interaction between epiplakin 1 and keratin filaments, enhancing its structural role. Lithium chloride inhibits GSK-3, which could promote the stabilization of intermediate filaments and, thereby, the association of epiplakin 1 with these structures.
Calyculin A and Okadaic acid, both inhibitors of protein phosphatases, can dephosphorylation of cytoskeletal proteins, which may indirectly lead to an enhanced functional state of epiplakin 1 as it interacts with intermediate filaments. Dibutyryl-cAMP, a cAMP analog, and 1,2-Dioctanoyl-sn-glycerol, a DAG analog, both act similar to Forskolin and PMA, respectively, by activating PKA and PKC, potentially affecting epiplakin 1's role in filament organization. Retinoic acid can induce differentiation in epithelial cells, potentially leading to cytoskeletal reorganization and enhancing epiplakin 1's role. Staurosporine, although a broad kinase inhibitor, can selectively influence kinase activity at low concentrations, potentially affecting epiplakin 1's phosphorylation state. Cyclosporin A, through the inhibition of calcineurin, may lead to a sustained phosphorylation state of proteins, which can support epiplakin 1's function. Lastly, Isoproterenol, as a beta-adrenergic agonist, can elevate cAMP, which, through PKA activation, could enhance the activity of epiplakin 1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an activator of adenylate cyclase, leading to increased cAMP levels within cells. Elevated cAMP can activate protein kinase A (PKA), which can phosphorylate various proteins, potentially enhancing the cytoskeletal association of epiplakin 1 by affecting the phosphorylation state of intermediate filament proteins. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). PKC phosphorylates target proteins involved in cell adhesion and cytoskeletal organization. Phosphorylation changes can influence the binding capacity and localization of epiplakin 1 within the cytoskeletal framework, enhancing its functional activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 can stabilize cytoskeletal proteins and may enhance the structural support role of epiplakin 1 by promoting the integrity of keratin intermediate filaments. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is an inhibitor of protein phosphatases 1 and 2A, leading to increased phosphorylation of cellular proteins. This can affect the cytoskeletal network and potentially increase the functional engagement of epiplakin 1 with intermediate filaments by preventing their dephosphorylation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog that activates PKA. Activation of PKA can lead to the phosphorylation of cytoskeletal proteins, potentially enhancing the interaction between epiplakin 1 and keratin intermediate filaments. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid can influence cellular differentiation processes. In epithelial cells, this can lead to the remodeling of the cytoskeleton, which may enhance the role of epiplakin 1 in stabilizing intermediate filaments during differentiation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases, primarily PP1 and PP2A, leading to an increase in the phosphorylation state of proteins. This can enhance the structural integrity of intermediate filaments and potentially promote the association of epiplakin 1 with these cytoskeletal elements. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a nonspecific kinase inhibitor, but at low concentrations, it can preferentially inhibit certain protein kinases. This selective inhibition can lead to altered phosphorylation patterns, potentially enhancing the functional role of epiplakin 1 in the context of cytoskeletal dynamics. | ||||||
1,2-Dioctanoyl-sn-glycerol | 60514-48-9 | sc-202397 sc-202397A | 10 mg 50 mg | $47.00 $254.00 | 2 | |
This synthetic analog of diacylglycerol activates PKC, which is involved in the regulation of cytoskeletal organization. PKC activation can enhance the association of epiplakin 1 with the intermediate filament network. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that binds to the cytosolic protein cyclophilin, inhibiting the phosphatase activity of calcineurin. By inhibiting calcineurin, it can indirectly enhance the phosphorylation state of cytoskeletal proteins, potentially supporting the functional role of epiplakin 1 in cytoskeletal stabilization. | ||||||